A New Risk Index Combining -Dimer, Fibrinogen, HE4, and CA199 Differentiates Suspecting Endometrial Cancer From Patients With Abnormal Vaginal Bleeding or Discharge

A New Risk Index Combining -Dimer, Fibrinogen, HE4, and CA199 Differentiates Suspecting Endometrial Cancer From Patients With Abnormal Vaginal Bleeding or Discharge

Blog Article

Purpose: To establish an efficient new risk index for screening patients with endometrial cancer from patients with abnormal vaginal bleeding or discharge.Method: A total of 254 patients with abnormal vaginal bleeding or discharge were included in this study.Several candidate markers, including HE4, CA125, CA199, CA153, AFP, CEA, SPF30 LIP BALM d -dimer, and fibrinogen, were employed.

A new risk index for endometrial cancer screening was established by binary logistic regression.The diagnostic value of the candidate markers and the new risk index were assessed by a receiver operating characteristic curve, sensitivity, and specificity.Results: The most valuable diagnostic indicator for endometrial cancer was HE4, followed by d -dimer and then fibrinogen (area under the receiver operating characteristic curve: HE4 = 0.

794, d -dimer = 0.717, fibrinogen = 0.690).

The new risk index was superior to a single application of markers and a widely used combination (HE4 and CA125).At the ideal cutoff level, the sensitivity and specificity were 91.34% and 70.

08%, respectively.In addition, only patients without organic disease served as controls, which further increase its performance (area under the receiver operating characteristic curve = 0.932, sensitivity Peizo Ignitor = 94.

49%, and specificity = 77.42%).Conclusions: The new risk index combining HE4, d -dimer, fibrinogen, and CA199 was the ideal combination for the screening of endometrial cancer.

As a simple, rapid, nondestructive detection method, the new risk index is worth promotion in clinical practice, especially in primary medical institutions.